Crinetics Clears Antitrust Hurdles; Shareholder Vote Set for Aug 28
CRNX has more than doubled off its 52-week low of $28.62 on light trading volume (0.3× avg).
Summary
Crinetics announced that the HSR waiting period expired and antitrust approvals were received in Austria, Germany, and Australia. A shareholder vote is set for August 28, 2026, with closing expected in early September.
Key Events · M&A and Partnerships · CRNX
-
HSR Waiting Period Expired
The Hart-Scott-Rodino waiting period expired at 12:45 p.m. ET on August 12, 2026, clearing U.S. antitrust review for the Vertex acquisition.
-
International Antitrust Approvals Received
As of August 13, 2026, approvals required under antitrust laws in Austria, Germany, and Australia have been received, subject to an Australian waiting period expiring August 27, 2026.
-
Shareholder Vote Scheduled
A special meeting of Crinetics shareholders to adopt the merger agreement is scheduled for August 28, 2026.
-
Expected Closing Timeline
Assuming shareholder approval, the merger is expected to close in early September 2026.
Analysis · CRNX · Life Sciences
The HSR waiting period expired and antitrust approvals were received in Austria, Germany, and Australia, clearing major regulatory hurdles for the $10 billion Vertex acquisition. The special shareholder meeting is now scheduled for August 28, 2026, with closing expected in early September. This materially de-risks the deal and provides a concrete timeline for completion.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRNX was trading at $84.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $28.62 to $84.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.